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skin-infiltrating leukocytes in AA of C3H/HeJ mice and that
IL-10/ mice are resistant to the development of AA,
pointing toward an involvement of type 2 cytokines in AA
pathogenesis. To prove the functional relevance of type 1
cytokines in AA, we induced AA in IFN-g/ mice and in IL-
2þ / mice by grafting lesional AA skin from AA-affected
mice.
Conclusions
Our data show that IFN-g/ mice are resistant to the
development of AA, pointing toward an important role of
IFN-g in the pathogenesis of AA. The absence of a
perifollicular lymphocytic infiltrate in the skin and the
reduced expression of T cell activation markers and co-
stimulatory molecules in skin-draining lymph nodes demon-
strate that T cells are not activated in the lymph nodes of
IFN-g/ mice. Therefore, we conclude that IFN-g is
involved in T cell activation in AA pathogenesis of C3H/
HeJ mice.
A pathogenetic role for IL-2 in AA could also be
demonstrated, but the cogency of our data is limited
because only heterozygous IL-2þ / mice were available
for these experiments. But Holla¨nder et al (Science 1998)
demonstrated that IL-2 expression is reduced 50% in IL-
2þ / mice compared with IL-2þ /þ mice. Our data show
that the frequency of AA development is significantly
reduced in IL-2þ / mice. Therefore, we conclude that
the magnitude of IL-2 expression influences the frequency
of AA development. FACS analysis and immunohistochem-
istry show that AA resistance of half of the IL-2þ / mice is
related to a reduced Tcell activation in the lymph nodes and
an absence of perifollicular infiltrates of CD4þ and CD8þ
cells in the skin. These data suggest that AA development in
the C3H/HeJ mouse model depends on the level of IL-2
expression and on subsequent T cell activation in the lymph
nodes.
Taken together, our results show that the type-1
cytokines IFN-g and IL-2 are involved in T cell activation in
the development of AA in the C3H/HeJ mouse model.
Methods and Results
After experimental induction of AA by skin grafting, 90% of normal
C3H/HeJ mice (control) developed AA, whereas none of the IFN-
g/ mice and only 47% of IL-2þ / mice developed AA.
Immunohistochemistry of skin sections showed dense peri- and
intrafollicular infiltrates of CD4þ and CD8þ cells in control mice
with AA, whereas perifollicular infiltrates were absent in IFN-g/
and IL-2þ / mice without AA.
FACS analysis of skin-draining lymph node cells and skin-
infiltrating leukocytes of IFN-g/ mice revealed a significant
reduction of the T cell activation markers and of co-stimulatory
molecules. In IL-2þ / mice the expansion of CD4þ T cells was
reduced and the upregulation of activation markers and costimu-
latory molecules was impaired.
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We pioneered anticytokine therapy, proposing anti-IFN
(interferon) and anti-TNF-a (tumor necrosis factor) to treat
autoimmune diseases (AD) (Skurkovich et al, 2002).
Evidence is accumulating that alopecia areata (AA) may
be a Th-1 mediated AD of the hair follicle (Arca et al, 2004).
Based on this and our hypothesis that all Th1 AD may have
a similar basis—disturbed IFN-g synthesis—with varying
clinical manifestations depending on the site of the
disturbance (Skurkovich et al, 2002), we administered
anti-IFN-g intramuscularly (IM) to patients with AA. Anti-
IFN-g antibodies were produced by immunizing goats with
recombinant human IFN-g, isolating the IgG, and preparing
F(ab0)2 fragments. Sixteen AA patients (age 6–15 years)—
nine with patchy, progressive disease (positive hair pull test
at periphery of patches), five with 100% scalp hair loss,
some with eyebrows and/or eyelashes preserved, and two
patients with patchy, stable hair loss were treated. Duration
of illness ranged from 6 m to 5 y (mean 2.75 y), size of areas
of hair loss from 3 to 12 cm in diameter, and the number of
patches of hair loss from 1 to 4. Patients were given 1 mL IM
injections of anti-IFN-g twice daily for five successive days.
Most patients were observed monthly up to 6 mo after
completion of therapy. AA was accompanied by psoriasis
vulgaris and vitiligo in one patient each.
Of the 16 patients treated, eight of the nine patients with
patchy, progressive hair loss stabilized after 3 days of
therapy and showed no additional hair loss. After 4–6 mo
(with one patient observed only 3 mo), these patients
showed partial, but on-going (four), or full (four) terminal,
i.e., fully restored, hair-growth including eyebrows and/or
eyelashes, with one having no response. By 6 mo only one
of these patients had any recurrence (one 1.5 cm lesion
which appeared 5 mo post-treatment) with the rest
maintaining or continuing their improvement. Of the five
patients with 100% baldness, three had some limited
terminal hair growth; the other two showed only vellus hair
or no response. Of the two patients with stable, patchy hair
loss, one showed complete eyelash and eyebrow hair
restoration, but neither showed scalp hair growth.
The accompanying cases of vitiligo and psoriasis also
improved, confirming good results using anti-IFN-g to treat
these diseases. Since best results were obtained in patients
with patchy, progressive hair loss (positive hair pull test at
periphery of patches), the results support early intervention
as most effective. In the cases of total hair loss, repeated
courses of injection, possibly with humanized monoclonal
antibodies, may give a better outcome. The immediacy and
high rate of response to the injections argue against
spontaneous remission of the disease as an explanation
for the improvement.
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In future, we plan to give humanized monoclonal anti-
IFN-g antibodies to AA patients.
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